Website sponsors

The BSMO website is supported by:

News from sponsors

Opdivo is reimbursed as of 1st of January in Lung (NSCLC), RCC (renal) and Hodgkin in monotherapy, as well as in melanoma in combination with Yervoy.

More information can be read in the article of BMS (PDF)
www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003985/WC500189765.pdf 

TECENTRIQ is reimbursed as of the 1st of January in urothelial carcinoma (UC) &  non-small cell lung cancer (NSCLC).

More information can be read in the Letter (PDF)

The cancer immunity cycle: a framework for cancer immunotherapy

More information can be read in the article of Roche (PDF)